Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Earnings Call Transcript: Key Takeaways

Like-for-like growth ~20% and ex-IGI EBITDA margin 21%, yet H1 operating cash was negative; H2 cash recovery is the test.

Glenmark Pharmaceuticals Investor Presentation: Key Takeaways

Q2 FY27 consolidated revenue Rs 42,473 Mn, down 29.8% YoY on a reported basis. EBITDA Rs 8,638 Mn (20.3% margin); Adj PAT Rs 4,852 Mn (11.4% margin). North America headline is flattered by ISB 2001 licensing income.

Glenmark Pharmaceuticals Results Update

Glenmark Pharmaceuticals released its Q2 FY27 press release and MD&A for the quarter ended September 2026. Highlights show India growth and lower North America revenue.

Glenmark Pharmaceuticals Q2 FY27 Results: Net Profit ₹263.8 Cr, Down 56.8% YoY

Glenmark Pharmaceuticals Ltd reported revenue from operations of ₹4,247 Cr (-29.8% YoY) and net profit of ₹263.8 Cr (-56.8% YoY) for Q2 FY27.

Key figure

Net profit ₹263.8 Cr · -56.8% YoY

Glenmark Pharmaceuticals Other Announcement

Glenmark's partner IGI will present updated Phase 1 clinical data for ISB 2001 (ABBV-2001) in relapsed/refractory multiple myeloma at the 68th ASH Annual Meeting. The presentation is scheduled for December 12, 2026.

Glenmark Pharmaceuticals Board Meeting Date

Glenmark Pharmaceuticals notified BSE of a board meeting on 05 Nov 2026 to consider unaudited Q2 FY27 results. No financial figures are disclosed in this advance intimation.

Glenmark Pharmaceuticals Other Announcement

Glenmark Pharmaceuticals has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI Regulation 31(1)(b).

Glenmark Pharmaceuticals Product Launch

Glenmark Pharmaceuticals launched Adapalene Gel USP, 0.1% (OTC) in new pump packs in the USA, expanding its dermatology portfolio.

Glenmark Pharmaceuticals Business Update

Glenmark Pharmaceuticals received an Establishment Inspection Report from the U.S. FDA for its Goa facility, which has been assigned a Voluntary Action Indicated status.

Glenmark Pharmaceuticals Annual General Meeting

Glenmark Pharmaceuticals held its 48th Annual General Meeting on September 11, 2026. The company submitted the proceedings, Scrutinizer’s Report, and voting results to the exchanges.

Glenmark Pharmaceuticals Product Launch

Glenmark Pharmaceuticals launched RYALTRIS® nasal spray in Brazil to treat moderate to severe allergic rhinitis, expanding its global respiratory product footprint in Latin America.

Glenmark Pharmaceuticals Credit Rating

India Ratings upgraded Glenmark Pharmaceuticals' long-term bank loans to 'IND AA+' and affirmed short-term ratings at 'IND A1+'.

Glenmark Pharmaceuticals Product Launch

Glenmark Pharmaceuticals Inc., USA has launched Calcium Gluconate Injection USP in various dosages. This launch expands the company's injectable portfolio and presence in the U.S. hospital market.

Glenmark Pharmaceuticals Business Update

Glenmark Pharmaceuticals received U.S. FDA approval for its Fluticasone Propionate Nasal Spray. The product will be distributed in the U.S. market.

Glenmark Pharmaceuticals Other Announcement

Glenmark Pharmaceuticals released its Business Responsibility & Sustainability Report for the financial year 2025-26. This filing adheres to SEBI's regulatory disclosure requirements.

Glenmark Pharmaceuticals Annual General Meeting

Glenmark Pharmaceuticals Limited has issued the notice for its 48th Annual General Meeting, scheduled to be held on September 11, 2026, through video conferencing.

Glenmark Pharmaceuticals Legal & Regulatory

Glenmark Pharmaceuticals agreed to a $15.28 million settlement with Humana, Inc. to resolve antitrust litigation. This payment has been fully provided for in the company's financials.

Value

₹145.3 Cr

Glenmark Pharmaceuticals Employee Stock Options

Glenmark Pharmaceuticals Limited has allotted 23,863 equity shares following the exercise of options under its ESOP 2016 scheme. This allotment increases the company's paid-up capital to Rs. 28,22,24,672.

Glenmark Pharmaceuticals Earnings Call Transcript: Key Takeaways

Glenmark reported Q1 FY27 consolidated revenue of INR 40,185 million, a 23.1% YoY increase. Performance was driven by India growth (15.5%) and North America recovery (41.1%).

Call

Guides 15% growth

Glenmark Pharmaceuticals Earnings Call Transcript: Key Takeaways

Glenmark delivered robust 23.1% revenue growth for Q1 FY27, driven by strong recovery in North America and steady India outperformance, despite persistent geopolitical cost pressures.

Call

Guides 15% growth

Glenmark Pharmaceuticals Investor Presentation: Key Takeaways

Glenmark reported strong Q1 FY27 results with consolidated revenue of Rs. 40,185 million, representing 23.1% YoY growth. Strategy focuses on core business strengthening and expanding innovation-led platforms like RYALTRIS®.

Glenmark Pharmaceuticals Results Update

Glenmark Pharmaceuticals reported Q1 FY27 consolidated revenue of ₹4,018.5 Crore, a 23.1% YoY growth, with an EBITDA of ₹804.8 Crore.

Value

₹4,018 Cr

Glenmark Pharmaceuticals Other Announcement

Glenmark Pharmaceuticals updated its list of key officials authorized to determine event materiality and manage stock exchange disclosures under Regulation 30(5) of SEBI LODR.

Glenmark Pharmaceuticals Q1 FY27 Results: Net Profit ₹482.8 Cr, Up 927.2% YoY

Glenmark Pharmaceuticals Ltd reported revenue from operations of ₹4,018 Cr (+23.1% YoY) and net profit of ₹482.8 Cr (+927.2% YoY) for Q1 FY27.

Key figure

Net profit ₹482.8 Cr · +927.2% YoY

Glenmark Pharmaceuticals Product Launch

Glenmark Pharmaceuticals launched Sugammadex Injection in the U.S. market. This addition strengthens the company's injectable portfolio and presence in the hospital segment.

Glenmark Pharmaceuticals Regulatory Approval

Glenmark received U.S. FDA approval to expand the use of its RYALTRIS nasal spray to pediatric patients aged 6 to less than 12 years.

Glenmark Pharmaceuticals Board Meeting Date

Glenmark Pharmaceuticals scheduled a board meeting on July 31, 2026. The board will consider and approve unaudited financial results for the quarter ended June 30, 2026.

Glenmark Pharmaceuticals Product Launch

Glenmark advanced its Phase 3 trial for Trastuzumab rezetecan in ovarian cancer. India is first to enroll, with plans for Australia and South Korea pending approvals.

Glenmark Pharmaceuticals Business Update

Glenmark's Goa facility received a US FDA Form 483 with six procedural observations. The company expects no impact on commercial product supply.

Glenmark Pharmaceuticals Earnings Call: Key Takeaways

Glenmark aims to become a US$2bn+ revenue company by FY26, shifting its portfolio mix toward >70% branded products by FY30e through global innovation in Oncology, Respiratory, and Dermatology.